GEOVAX LABS INC (GOVX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.48-4.68%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · GOVX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -84.3% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
GOVX — legal / regulatory event — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standar…
Dated 2026-08-28
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On August 27, 2026, GeoVax Labs Inc. (the “Company”) received a Staff Determination Letter (the “Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Staff has determined to delist the Company’s common stock from Nasdaq. As set forth in the Letter states, the closing bid price of the Company’s common stock was below the $1…
Why it matters: Staying compliant is key to keeping the stock's listing. A delisting could hurt investor trust and funding.
Worry ifGeoVax has at least $2.5 million in stockholders' equity.
Less concerning ifOngoing non-compliance with Nasdaq rules may lead to a delisting.
Why it matters: This trial is important for getting approval. It may also help investors feel more confident.
Supportive ifAnnouncement of the Phase 3 trial initiation for GEO-MVA in the second half of 2026.
Worry ifDelay or cancellation of the Phase 3 trial initiation.
Why it matters: The company is pursuing M&A to boost growth. Progress could signal future revenue potential.
Supportive ifThe company announces a successful M&A deal that adds significant value.
Worry ifNo new M&A activity is reported, and revenue remains at zero.
Why it matters: The company needs private placements for funding. Success or failure affects financial health.
Watch forThe company completes a private placement raising at least $2M.
Also watch forThe company fails to raise the expected money through private placements.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$521 on $10,000 · ±5.2% | How much price usually moves either way. |
| Bad day | $1,337 loss on $10,000 · 13.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,730 loss on $10,000 · 97.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Starting this study is crucial for regulatory approval of the GEO-MVA vaccine. It shows progress in addressing global vaccine supply needs.
Supportive ifThe GEO-MVA immunobridging study starts in Q4 2026 as planned.
Worry ifThe GEO-MVA immunobridging study is delayed past Q4 2026.
Why it matters: Gedeptin's progress could help it earn more money in cancer care.
Supportive ifGeoVax will announce a new partnership or trial results for Gedeptin next quarter.
Worry ifNo new news or partnerships for Gedeptin are reported next quarter.
Why it matters: How GeoVax deals with the delisting notice will impact trust and stock price.
Worry ifGeoVax meets Nasdaq's listing rules and avoids delisting.
Less concerning ifGeoVax does not meet Nasdaq's rules and gets delisted.
Why it matters: Changes in cash position show financial health and ability to fund projects.
Watch forGeoVax has more cash after successful fundraising efforts.
Also watch forGeoVax has less cash or is facing money problems.